BridgeBio Pharma (BBIO) Total Current Liabilities (2018 - 2026)

BridgeBio Pharma's Total Current Liabilities history runs 9 years deep, the most recent figure standing at $816.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 436.72% year-over-year to $816.4 million; the TTM figure through Mar 2026 stood at $816.4 million (up 436.72% YoY), while the FY2025 annual figure was $288.0 million, up 86.51% from the prior year.
• Total Current Liabilities came in at $816.4 million for Q1 2026 at BridgeBio Pharma, up from $288.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $816.4 million in Q1 2026 to a low of $96.6 million in Q1 2023.
• A 5-year average of $185.9 million and a median of $141.2 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities dropped 21.99% in 2023 and soared 436.72% in 2026, its largest moves.
• BridgeBio Pharma's Total Current Liabilities stood at $121.4 million in 2022, then grew by 18.46% to $143.8 million in 2023, then advanced by 7.34% to $154.4 million in 2024, then soared by 86.51% to $288.0 million in 2025, then surged by 183.49% to $816.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $816.4 million, $288.0 million, and $216.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison